103 related articles for article (PubMed ID: 15195971)
1. Enhanced expression of an antibody-targeted plasminogen activator in Escherichia coli by fusion to decorsin.
Yu M; Yu M; Ru B
Biotechnol Lett; 2004 May; 26(9):717-21. PubMed ID: 15195971
[TBL] [Abstract][Full Text] [Related]
2. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
3. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.
Kawano K; Aoki I; Aoki N; Homori M; Maki A; Hioki Y; Hasumura Y; Terano A; Arai T; Mizuno H; Ishikawa K
Am Heart J; 1998 Feb; 135(2 Pt 1):268-71. PubMed ID: 9489975
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of trifunctional single-chain urokinase-type plasminogen activators.
Bi Q; Cen X; Huang Y; Zhu S
Eur J Biochem; 2002 Mar; 269(6):1708-13. PubMed ID: 11895441
[TBL] [Abstract][Full Text] [Related]
6. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
7. Expression of an antibody-targeted plasminogen activator in Escherichia coli using chemically induced stress responses.
Yu M; Yu M; Ru B
Biotechnol Lett; 2004 Nov; 26(21):1629-34. PubMed ID: 15604810
[TBL] [Abstract][Full Text] [Related]
8. Remaining perspectives of mutant and chimeric plasminogen activators.
Lijnen HR; Collen D
Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
11. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
12. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterization of the ScFv fragment of antiplatelet GPIIIa monoclonal antibody SZ-21.
An G; Dong N; Shao B; Zhu M; Ruan C
Thromb Res; 2002 Feb; 105(4):331-7. PubMed ID: 12031828
[TBL] [Abstract][Full Text] [Related]
15. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K
Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase.
Jiao J; Yu M; Ru B
Biochimie; 2001; 83(11-12):1049-55. PubMed ID: 11879733
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
18. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the promoter and ribosome binding sequence for expression of human single chain urokinase-like plasminogen activator in Escherichia coli and stabilization of the product by avoiding heat shock response.
Surek B; Wilhelm M; Hillen W
Appl Microbiol Biotechnol; 1991 Jan; 34(4):488-94. PubMed ID: 1367523
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of thrombolytic enzymes].
Matsuo O
Rinsho Ketsueki; 1993 Apr; 34(4):395-402. PubMed ID: 8510325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
